semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.167-999.0,  Skeletal Abnormalities Psychomotor Retardation Informed consent will be obtained from the parents before any study related procedures Patients of both genders older than 2 month The patient has a diagnosis of Mucolipidosis Disorder type I,II,III or IV or high-grade suspicion for Mucolipidosis Disorder type I,II,III or IV High-grade suspicion present, if one or more are valid: Positive family anamnesis for Mucolipidosis Disorder type I,II,III or IV Skeletal abnormalities Psychomotor retardation Progressive failure to thrive Hoarse voice  No Informed consent from the parents before any study related procedures Patients of both genders younger than 2 month No diagnosis of Mucolipidosis Disorder type I,II,III or IV or no valid for profound suspicion of Mucolipidosis Disorder type I,II,III or IV
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 8.0-18.0,  Posttraumatic Stress Disorder Depression Anxiety Aged between 8 and 18 years Admission to hospital for accidental injury involving danger to life, serious injury or impairment Admission to hospital for acute illness involving danger to life, serious injury or impairment Sudden severe impairment of medical condition Admission of parent or sibling to hospital for accidental injury involving danger to life, serious injury or impairment Admission of parent or sibling to hospital for acute illness involving danger to life, serious injury or impairment Sudden severe impairment of parental or sibling medical condition Consent to participate in the study  Parent's Danish insufficient for questionnaire completion Developmental delay or mental retardation in the child Moderate to severe head injury or posttraumatic amnesia following the accident Injury due to physical or sexual abuse (intentional injury)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-45.0,  Infants of Diabetic Mothers (understood to only abstemious women) 1. . Pregnant women expected to deliver between 37 and 41 weeks gestation (controls), and their babies 2. . Pregnant women expected to deliver between 37 and 41 weeks gestation who have class A1 diabetes mellitus, and their babies 3. . Pregnant women expected to deliver between 37 and 41 weeks gestation who have class A2 diabetes mellitus, and their babies 4. . Pregnant women expected to deliver between 37 and 41 weeks gestation who were diagnosed with diabetes mellitus prior to their pregnancy, and their babies  . Mothers who self-reported any alcohol or any illicit drug use during their pregnancy (and their babies) 2. . Mothers who had a positive drug screen at any point during their pregnancy (and their babies) 3. . Babies whose mothers suffered a placental abruption during their pregnancy. 4. . Babies whose mothers had inadequate prenatal care (defined as <3 prenatal clinic visits prior to admission for delivery) 5. . Non-English-speaking mothers 6. . Babies who pass meconium in utero. 7. . Babies born with multiple congenital anomalies or abdominal wall defects
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-999.0,  Dwarfism, Pituitary Before starting treatment, according to the medical history, clinical symptoms and signs, GH stimulation test and imaging examination, patients are diagnosed as GHD According to the height statistical data of Chinese children's physique development in nine cities in 2005, height is lower than the third percentile of growth curve of normal children with the same age and gender Height velocity (HV) ≤5.0 cm/yr GH stimulation test with two different mechanisms affirms that GH peak concentration of patients' plasma <10.0ng/ml Bone age (BA) ≤9 years in girls and ≤10 years in boys, at least 1 year less than his/her chronological age (CA) Be in preadolescence (Tanner stage 1) and have a CA ≧ 3 years Receive no prior GH treatment within 6 months Sign informed consent  People with abnormal liver or kidney function (ALT> 2 times the upper limit of normal value, Cr> the upper limit of normal value) Patients positive for hepatitis B core antigen (HBc), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) People with known highly allergic constitution or allergy to the drug of the study People with severe cardiopulmonary, hematological and malignant tumors diseases or general infection and immune deficiency Potential tumor patients (family history) Diabetic Abnormal growth and development, such as Turner syndrome, constitutional delay of growth and puberty, Laron syndrome, growth hormone receptor deficiency, girls of growth retardation without excluding abnormal chromosome Subjects took part in other clinical trial study within 3 months Other conditions which in the opinion of the investigator preclude enrollment into the study
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-17.0,  Growth and Development Pediatric female patients who were on study treatment in study [CRAD001M2301] within the past 63 months and have not reached Tanner Stage V or age 16 at the time of completion of [CRAD001M2301] or Pediatric male patients who were on study treatment in study [CRAD001M2301] within the past 6 months and have not reached Tanner Stage V or age 17 at the time of completion of [CRAD001M2301] Written informed consent according to local guidelines  Pediatric female patients who were on study treatment in CRAD001M2301 and have not reached Tanner Stage V but are within 3 month of turning age 16 or Pediatric male patients who were on study treatment in CRAD001M2301 and have not reached Tanner Stage V but are within 3 months of turning age 17 Any patient who was pregnant prior to start of CRAD001M2305 Other protocol-defined Inclusion/
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atrial Fibrillation ≥ 18 years of age Patients of African, European, and Hispanic descent History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF ECG that was recorded within 1 month of randomization showing AF Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD Able to give informed consent  Permanent AF or isolated atrial flutter Cardiac or thoracic surgery within the previous 6 months Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital) Medical condition that is likely to be fatal in less than one year A history of prior AF ablation Have already been tried on 2 or more AADs in the past for AF Creatinine clearance <40 ml/min Left ventricular ejection fraction < 50% Contra-indication to a Class I AAD e.g., structural heart disease, or history of MI Contra-indication to a Class III AAD, e.g., congenital or acquired long QT syndrome with QTc>480 ms in females and >460 ms in males at baseline
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 7.0-12.0,  Auditory Processing Disorder Normal audiogram. 2. Diagnosis of APD based on clinical tests administered by qualified audiologists as per the clinic's diagnosis protocol. 3. No neurological or pervasive disorder or developmental delay (e.g. Attention Deficit Hyperactivity Disorder, epilepsy, Autism Spectrum Disorder, Developmental Language Disorder, Down Syndrome). 4. Non-verbal cognitive ability score of 85 or greater. 5. Ages between 7-12 years. 6. Native English speakers. 7. No prior use of RMHAs  Any violation of the above conditions
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Growth Hormone Deficiency Before starting treatment, according to the medical history, clinical symptoms and signs, GH stimulation test and imaging examination, patients are diagnosed as GHD According to the height statistical data of Chinese children's physique development in nine cities in 2005,height is lower than the third percentile of growth curve of normal children with the same age and gender Height velocity (HV) ≤5.0 cm/yr GH stimulation test with two different mechanisms affirms that GH peak concentration of patients' plasma<10.0ng/ml Bone age (BA) ≤9 years in girls and ≤10 years in boys, at least 1 year less than his/her chronological age (CA) Be in preadolescence (Tanner stage 1) and have a CA ≧ 3 years Receive no prior GH treatment within 6 months Sign informed consent  People with abnormal liver or kidney function (ALT> 2 times the upper limit of normal value, Cr> the upper limit of normal value) Patients positive for hepatitis B core antigen (HBc), hepatitis B surface antigen (HBsAg) or hepatitis Be antigen (HBeAg) People with known highly allergic constitution or allergy to the drug of the study People with severe cardiopulmonary, hematological and malignant tumors diseases or general infection and immune deficiency Diabetic Potential tumor patients (family history) Abnormal growth and development, such as Turner syndrome, constitutional delay of growth and puberty,Laron syndrome, growth hormone receptor deficiency, girls of growth retardation without excluding abnormal chromosome Subjects took part in other clinical trial study within 3 months Other conditions which in the opinion of the investigator preclude enrollment into the study
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-15.0,  Growth Problem Low Weight Short Stature Boys aged ≥10years old Prepubertal Tanner stage 1 (gonadarche) (testicular volume<4) Height and weight ≤ 10th percentile for age and gender Height-SDS ≥ -2.5 SDS BMI-SDS>-3 SDS Low proportion between weight and height Signing inform consent forms  Diagnosis of Growth Hormone (GH) Deficiency or treatment with GH Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardiac, renal or pulmonary problems Any known gastrointestinal disease including malabsorption Any known organic reason for growth retardation
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 9.0-14.0,  Growth Problem Low Weight Girls aged ≥9 years old Prepubertal Tanner stage 1. (gonadarche) Breast at Tanner stage 1) Height and weight ≤ 10th percentile for age and gender Height-SDS ≥ -2.5 SDS BMI-SDS>-2 SDS Low proportion between weight and height Signing inform consent forms  Diagnosis of Growth Hormone (GH) Deficiency or treatment with GH Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardiac, renal or pulmonary problems Any known gastrointestinal disease including malabsorption Any known organic reason for growth retardation Any chronic treatment with medication that might affect appetite, weight or growth (for example SSRI's)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Vitamin D Deficiency Obese subjects BMI at or above the 95th percentile for children of the same age and sex. Only obese subjects will be selected given that they are the highest risk group of developing insulin resistance and Type II Diabetes and therefore with be most likely to demonstrate glucose pertubation. 2. Pubertal: Testicular volume ≥ 6 ml Prader (M) and Tanner III breast development or greater (F) 3. 12 years regardless of gender, race or economic circumstance 4. Pre diabetes/high risk of diabetes using of HbA1C between 5.7 4% as defined by the American Diabetes Association (ADA) 5. 25-OH vitamin D level less than 20 ng/ml (50 nmol/liter) 6. Subjects must be willing to comply with study protocol requirements  Treatment on medication known to effect vitamin D, calcium and glucose metabolism, such as glucocorticoids, thiazolidinediones, metformin, anticonvulsants metabolized through cytochrome P-450 (phenytoin, carbamazepine, phenobarbital, sodium valproate). 2. Subjects will be excluded from the study if they have taken any form of vitamin D supplementation greater than 400 IU daily in the preceding 3 months. 3. Significant major organ system illness 4. History of nephrolithiasis or hypercalcemia 5. Females who are pregnant 6. Significant psychiatric illness: schizophrenia, bipolar disorder, active substance abuse, and uncontrolled major depression. 7. Attendance at tanning salon
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Puberty, Precocious Female gender Clinical suspicion of central precocious puberty A GnRH stimulation test is to be performed to make appropriate diagnosis  Age < 1 year Weight < 10 kg Untreated hypo or hyperthyroidism Diabetes of any kind BMI > 3 z-score Growth hormone treatment Syndrome or suspected syndrome Tumour or congenital malformation of the hypothalamus or the pituitary gland. (Neuroradiology does not have to be performed only because of the study.) On going ulcus ventriculi or the patient has gone through surgery that removed part of the ventricle or changed it markedly in any other way
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Atopic Dermatitis Food Allergy in Children Asthma Rhinitis, Allergic Non-communicable Diseases Obesity Cardiovascular Disease The study enrolls Mother-child pairs in two steps; first mother, thereafter her new-born baby. 1. Ante-natal step 1: All mothers to-be at 18 weeks ultrasound investigation with sufficient language skills (Norwegian or Swedish), gestational age: at least 16-22 weeks. 1. Plans to move further than reasonable travel distance from any of the participating hospitals within the first year of the offspring's life. 1. of the child, step 2: Live-born babies of gestational age 35.0 weeks or more (including multiple pregnancies), maternal/parental willingness to participate in the study  child: 1) severe neonatal cardiac, pulmonary, neurologic, dermatologic disease or other disease that may influence the outcomes 2), plans to move further than reasonable travel distance away from any of the participating hospitals within the first nine months of life. 3) Non-willingness to participate, 4) More than two foetuses
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-25.0,  Klinefelter Syndrome males between the ages of 12 and 25 diagnosed with mosaic or non-mosaic Klinefelter's Syndrome having bilaterally descended testes not having had a febrile illness within 3 months of enrollment  previous treated with gonadotoxic chemotherapeutic or radiation regimen psychological, psychiatric, or other conditions which prevent giving fully informed consent
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Fetuses With at Least 2 Malformations, and no Diagnosis After Fetopathological and Radiological Examinations Fetus with at least 2 malformations, with no diagnosis (or several low-certainty diagnostic hypotheses, which require several molecular examinations) after fetopathological and radiological examinations Written consent from both parents Possibility to obtain samples from both parents  Refusal of parents to take part in the study Parents without National Health Insurance cover Parents under guardianship or in custody Impossibility to obtain samples from both parents Diagnostic hypothesis considered highly probable for which a molecular test cheaper that HTES is available
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-12.0,  Developmental Delays Study group children with developmental delays obtained written informed consent from parents  parents refused for participation of their children to the intervention failed to obtain the written informed consent from parents Control group children with normal development obtained written informed consent from parents parents refused for participation of their children to the intervention failed to obtain the written informed consent from parents